Performance data is updated to 30 April 2026.

BetaShares Global Healthcare Currency Hedged ETF

MER · #311 of 488 AUM · #165 of 293 1Y Return · #273 of 415 3Y Return · #245 of 282 5Y Return · #149 of 221

DRUG aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars.

Link to website

Stock Code

DRUG

Fund Manager

Betashares

Asset Class

Equities

AUM

$159.16M

MER (%)

0.57%

Listing Date

08/08/2016

Performance (% return)

Investment Focus

Themes

HealthHedged

Exposure Regions

World

Portfolio Breakdown

Holdings Breakdown(Top 10 Holdings are 50.90% of total assets)

Company Name	% assets
ELI LILLY & CO	8.20%
JOHNSON & JOHNSON	7.90%
ABBVIE INC	5.50%
UNITEDHEALTH GROUP INC	5.30%
ASTRAZENECA PLC	5.20%
ROCHE HOLDING AG	5.20%
MERCK & CO INC	4.00%
NOVARTIS AG	3.80%
THERMO FISHER SCIENTIFIC INC	3.00%
NOVO NORDISK A/S	2.80%

Sector	Allocation	% assets
Pharmaceuticals		48.4%
Biotechnology		15.8%
Health Care Equipment		15.3%
Life Sciences Tools & Services		7.9%
Managed Health Care		5.6%
Health Care Supplies		3.3%
Health Care Facilities		1.4%
Health Care Services		1.1%
Health Care Distributors		0.7%
Other		0.5%

Similar ETFs

Stock	Name	Fund Manager	AUM $	Listing Date	Asset Class	MER %	1 Year %
BNKS	Global Banks Currency Hedged ETF	Betashares	$183.41M	01/08/2016	Equities	0.57%	+42.18%
CURE	S&P Biotech ETF	Global X	$40.36M	12/11/2018	Equities	0.45%	+38.76%
CGHE	Claremont Global Fund (Hedged) Active ETF	Claremont	$0	12/02/2024	Equities	1.25%	-4.38%
DAOR	Aoris Int Fund (Class D) (Hedged) Active ETF	Aoris	$0	01/05/2023	Equities	1.15%	+0.82%
DFGH	Dimensional Global Core Equity Trust (AUD Hedged Class) – Active ETF	Dimensional	$0	13/11/2023	Equities	0.36%	+28.96%

Disclaimer

The information provided on ReviewETF.com.au is intended for general information and comparison purposes only. It is compiled and presented on a best-endeavours basis from publicly available sources, but we do not guarantee its accuracy, completeness, timeliness, or suitability for any particular purpose.

No content on this website constitutes financial advice, investment recommendation, solicitation, or an offer to buy or sell any securities. Past performance is not indicative of future results, and all investments carry risk, including the potential loss of capital.

The point of truth for any ETF is always the official product disclosure statement (PDS), website, and announcements from the ETF issuer/provider (e.g., Vanguard, BetaShares, iShares, VanEck, etc.). We link directly to these primary sources on each individual ETF page wherever possible—please verify all details there before making any decisions.

ReviewETF.com.au, its owner (Joshua), and any associated entities disclaim all liability for any loss or damage arising from the use of, or reliance on, information contained on this site. Users should seek independent professional financial advice tailored to their personal circumstances.

This website may contain links to third-party sites; we are not responsible for their content or privacy practices.

Last updated: January 2026